WOBURN, Mass.--(BUSINESS WIRE)--ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S.

Scilex Holding Company announced the publication of important dosing adjustments for GLOPERBA®, its liquid oral colchicine product for gout management, in a peer-reviewed journal. GLOPERBA® is unique ...

Colchicine oral tablet is available as both a generic and brand-name drug. Brand name Colcrys. It also comes in capsules that are also available as both a generic and brand-name drug. Brand name: ...

GLOPERBA® (colchicine oral solution) is the first and only liquid formulation of colchicine that offers precision dosing for at risk gout patients. Scilex recently received FDA approval for an updated ...

Avion Pharmaceuticals announced the launch of Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults. Gloperba is a ready-to-use solution for oral administration containing ...

WOBURN — ROMEG Therapeutics, an Woburn-based drug development company, announced that the United States Patent and Trademark Office has issued two additional U.S. patents that are directed to the ...

PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and ...

Colchicine is a generic prescription medication used to prevent gout flares and treat familial Mediterranean fever (FMF) in adults and certain children. Like most drugs, colchicine can cause side ...